BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, August 14, 2024, to discuss the financial results for the second quarter 2024 and provide a business update.
Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13747259.
To access the new Call me™ feature, which avoids having to wait for an operator, click here.
The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.53 |
Daily Change: | -0.19 -4.99 |
Daily Volume: | 198,414 |
Market Cap: | US$176.390M |
November 13, 2024 September 04, 2024 August 14, 2024 August 12, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB